Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria

The high prevalence of undiagnosed diabetes1 and the proportion of cases with evidence of complications at diagnosis 2 3 undoubtedly create a strong imperative for screening. In the United Kingdom, the National Screening Committee has the task of providing advice about established and newly proposed screening programmes and aims to evaluate these against specified criteria.4 This article evaluates screening for type 2 diabetes in relation to these criteria. #### Summary points Benefits of early detection and treatment of undiagnosed diabetes have not been proved Effectiveness of diabetes screening in reducing cardiovascular disease depends on disease prevalence, background cardiovascular risk, and risk reduction in those screened and treated Disadvantages of screening are important and should be quantified Universal screening is unmerited, but targeted screening in specific subgroups may be justified Clinical management of people with established diabetes should be optimised before a screening programme is considered The first group of issues considered by the National Screening Committee relates to the condition for which screening is proposed. In the case of type 2 diabetes, these issues are relatively uncontroversial. The scale of morbidity and mortality attributable to diabetes is not in question,5 and the longitudinal examination of cohorts has established the overall course of the condition.6 Undiagnosed diabetes is common7; it is not generally characterised by recognised symptoms and is as strongly associated with future risk as diagnosed diabetes.8 Up to 25% of people with diabetes have evidence of microvascular complications at diagnosis, 1 3 and extrapolation of the association between the prevalence of retinopathy and the duration of disease suggests that the true onset of diabetes occurs several years before it is recognised clinically.2 The National Screening Committee's criteria also state that all “cost-effective primary prevention interventions should have been implemented as far as practicable.”4 …

[1]  L. Irwig,et al.  Screening for Type 2 diabetes mellitus: a decision analytic approach , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[2]  M. Engelgau,et al.  Screening for NIDDM in Nonpregnant Adults: A review of principles, screening tests, and recommendations , 1995, Diabetes Care.

[3]  N. Wareham,et al.  Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.

[4]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[5]  R. Hamman Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). , 1992, Diabetes/metabolism reviews.

[6]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[7]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[8]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[9]  C. Shaw,et al.  Psychological impact of predicting individuals' risks of illness: a systematic review. , 1999, Social science & medicine.

[10]  C. Palmer,et al.  Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[11]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[12]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[13]  UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. , 1990, Diabetes research.

[14]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[15]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[16]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[17]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[18]  L. Bouter,et al.  Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors , 1997, Diabetes Care.

[19]  J. Richardson,et al.  Cost-Effectiveness of the Primary Prevention of Non-Insulin Dependent Diabetes Mellitus , 1997 .

[20]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[21]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[22]  S. Haffner,et al.  Evidence of bimodality of two hour plasma glucose concentrations in Mexican Americans: results from the San Antonio Heart study. , 1985, Journal of chronic diseases.

[23]  S. Yusuf,et al.  Dysglycaemia and risk of cardiovascular disease , 1996, The Lancet.

[24]  R. Hanson,et al.  Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes , 1994, BMJ.

[25]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.